Assessing Barriers and Facilitators to Implementation of Risk Minimization Programs in the USA and Europe: An Application of the Consolidated Framework for Implementation Research
Drug Safety · 19.11.2026
DOI: 10.1007/s40264-026-01751-w ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Safety, online erschienen am 19.11.2026. Verfasst von Meredith Y Smith und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Regulatory and Quality Sciences, Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los …. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: University of Southern California.
Abstract (Originalsprache)
BACKGROUND: New regulatory guidance from the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) emphasizes understanding implementation context to integrate risk minimization programs into healthcare delivery. OBJECTIVE: To demonstrate how to conduct a contextual analysis pre-program implementation (for a formative evaluation) and post-implementation (for a summative evaluation). METHODS: Two programs were selected: (1) the existing risk minimization program for valproate in Europe and (2) the proposed Risk Mitigation and Evaluation Strategy (REMS) in the USA for tanezumab. Data sources included: (1) a collated set of written statements from stakeholders at the EMA's 2017 Public Hearing for valproate and (2) the 2021 FDA Advisory Committee meeting transcript for tanezumab. Both documents were analyzed qualitatively using codes from the Consolidated Framework for Implementation Research (CFIR). RESULTS: From the valproate document, 26 determinants were identified as having affected the implementation and delivery of the risk minimization program, the majority of which were clustered in the inner setting, individuals, and implementation process domains. From the tanezumab document, ten determinants were identified as having the potential to affect REMS implementation, the majority of which clustered in the innovation and individuals domains. In both cases, more barriers than facilitators were identified. CONCLUSIONS: Multiple factors operating at multiple socioecological levels were affecting or had the potential to affect risk minimization program implementation and delivery in the healthcare system. Implementation frameworks such as the CFIR provide a comprehensive and systematic way to identify relevant factors. Findings can be used to guide selection of appropriate strategies to reduce barriers and leverage facilitators.
Autor:innen und Institutionen
- Department of Regulatory and Quality Sciences, Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA, USA. meredithysmith1@gmail.com.
- PPD, Evidera, Patient-Centered Research, Thermo Fisher Scientific, Waltham, MA, USA.
- Marketed Health Products Directorate, Health Canada, Ottawa, Canada.
- European Medicines Agency, Amsterdam, The Netherlands.
Förderung
- University of Southern California
Zitieren
APA
Smith, M. Y., Nguyen, V., Mouchantaf, R., & Bahri, P. (2026). Assessing Barriers and Facilitators to Implementation of Risk Minimization Programs in the USA and Europe: An Application of the Consolidated Framework for Implementation Research. Drug Safety. https://doi.org/10.1007/s40264-026-01751-w
Vancouver
Smith MY, Nguyen V, Mouchantaf R, Bahri P. Assessing Barriers and Facilitators to Implementation of Risk Minimization Programs in the USA and Europe: An Application of the Consolidated Framework for Implementation Research. Drug Safety. 2026. doi:10.1007/s40264-026-01751-w
BibTeX
@article{Smith2026,
author = {Smith, Meredith Y and Nguyen, Viviana and Mouchantaf, Rania and Bahri, Priya},
title = {Assessing Barriers and Facilitators to Implementation of Risk Minimization Programs in the USA and Europe: An Application of the Consolidated Framework for Implementation Research},
journal = {Drug Safety},
year = {2026},
doi = {10.1007/s40264-026-01751-w}
}
EUVIMED